IMMP

Neutral

Immutep advances autoimmune program while reviewing efti pathway

Immutep is advancing its IMP761 autoimmune program, with initial Phase I data expected in June, while conducting a root cause analysis for its eftilag...

marketscreener.com 2 weeks ago 0

Bearish

IMMP Investors Have Opportunity to Lead Immutep Limited Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is reminding investors of a class action lawsuit against Immutep Limited (NASDAQ: IMMP) for alleged securities fraud. The lawsuit ...

GlobeNewswire 3 weeks ago 0